These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 9694848

  • 1. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1.
    Nash P, Whitty A, Handwerker J, Macen J, McFadden G.
    J Biol Chem; 1998 Aug 14; 273(33):20982-91. PubMed ID: 9694848
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.
    Lomas DA, Evans DL, Upton C, McFadden G, Carrell RW.
    J Biol Chem; 1993 Jan 05; 268(1):516-21. PubMed ID: 8416956
    [Abstract] [Full Text] [Related]

  • 3. Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase.
    Nash P, Barry M, Seet BT, Veugelers K, Hota S, Heger J, Hodgkinson C, Graham K, Jackson RJ, McFadden G.
    Biochem J; 2000 Apr 15; 347(Pt 2):375-82. PubMed ID: 10749666
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B.
    Viswanathan K, Richardson J, Togonu-Bickersteth B, Dai E, Liu L, Vatsya P, Sun YM, Yu J, Munuswamy-Ramanujam G, Baker H, Lucas AR.
    J Leukoc Biol; 2009 Mar 15; 85(3):418-26. PubMed ID: 19052145
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.
    Viswanathan K, Liu L, Vaziri S, Dai E, Richardson J, Togonu-Bickersteth B, Vatsya P, Christov A, Lucas AR.
    Thromb Haemost; 2006 Mar 15; 95(3):499-510. PubMed ID: 16525579
    [Abstract] [Full Text] [Related]

  • 9. Serpins, the vasculature, and viral therapeutics.
    Richardson J, Viswanathan K, Lucas A.
    Front Biosci; 2006 Jan 01; 11():1042-56. PubMed ID: 16146796
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection.
    Chen H, Zheng D, Abbott J, Liu L, Bartee MY, Long M, Davids J, Williams J, Feldmann H, Strong J, Grau KR, Tibbetts S, Macaulay C, McFadden G, Thoburn R, Lomas DA, Spinale FG, Virgin HW, Lucas A.
    Antimicrob Agents Chemother; 2013 Sep 01; 57(9):4114-27. PubMed ID: 23774438
    [Abstract] [Full Text] [Related]

  • 12. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection.
    Nash P, Lucas A, McFadden G.
    Adv Exp Med Biol; 1997 Sep 01; 425():195-205. PubMed ID: 9433502
    [No Abstract] [Full Text] [Related]

  • 13. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R, Biliran H, Sager R, Sheng S.
    Cancer Res; 2000 Sep 01; 60(17):4771-8. PubMed ID: 10987285
    [Abstract] [Full Text] [Related]

  • 14. Protein engineering of chimeric Serpins: an investigation into effects of the serpin scaffold and reactive centre loop length.
    Bottomley SP, Stone SR.
    Protein Eng; 1998 Dec 01; 11(12):1243-7. PubMed ID: 9930674
    [Abstract] [Full Text] [Related]

  • 15. Heparin alters viral serpin, serp-1, anti-thrombolytic activity to anti-thrombotic activity.
    Li X, Schneider H, Peters A, Macaulay C, King E, Sun Y, Liu L, Dai E, Davids JA, McFadden G, Lucas A.
    Open Biochem J; 2008 Dec 01; 2():6-15. PubMed ID: 18949070
    [Abstract] [Full Text] [Related]

  • 16. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW, Kjoller L, Petersen HH, Andreasen PA.
    Biochem J; 1998 Jan 01; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [Abstract] [Full Text] [Related]

  • 17. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
    Barrett CD, Moore HB, Kong YW, Chapman MP, Sriram G, Lim D, Moore EE, Yaffe MB.
    J Trauma Acute Care Surg; 2019 Jan 01; 86(1):101-107. PubMed ID: 30575685
    [Abstract] [Full Text] [Related]

  • 18. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S, Lockett J, Meng Y, Biliran H, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S.
    Cancer Res; 2006 Apr 15; 66(8):4173-81. PubMed ID: 16618739
    [Abstract] [Full Text] [Related]

  • 19. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
    Kasza A, Petersen HH, Heegaard CW, Oka K, Christensen A, Dubin A, Chan L, Andreasen PA.
    Eur J Biochem; 1997 Sep 01; 248(2):270-81. PubMed ID: 9346278
    [Abstract] [Full Text] [Related]

  • 20. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A, Knockaert I, Declerck PJ.
    Biochemistry; 1996 Jun 11; 35(23):7474-81. PubMed ID: 8652525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.